ArticleFrontiers in microbiology2026
High-dose capsaicin exposure is associated with more severe inflammation, intestinal dysregulation, and IL-17 elevation in experimental autoimmune uveitis.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate whether capsaicin exposure increases the severity of experimental autoimmune uveitis (EAU) and to further characterize the associated alterations in intestinal homeostasis and immune regulation. Methods: Mice were orally administered different doses of capsaicin (CAP) from the day of EAU induction through the peak of disease on day 21. EAU severity was evaluated by fundus imaging, clinical scoring, and retinal histopathological scoring. Intestinal morphological changes were assessed by hematoxylin and eosin staining, while intestinal barrier integrity was evaluated by detecting colonic ZO-1 and MUC2 expression using immunofluorescence staining and enzyme-linked immunosorbent assays. IL-17A levels in the colon and spleen were quantified by ELISA. Fecal 16S rRNA gene sequencing, untargeted metabolomics, and colonic RNA sequencing were performed to characterize alterations in gut microbiota, metabolic profiles, and inflammatory pathways. Based on the identification of reduced kynurenic acid (KYNA) levels, KYNA co-treatment was subsequently performed to evaluate its effects on ocular inflammation, IL-17A levels, and intestinal barrier-related alterations during high-dose CAP exposure. Results: In the 80 mg/kg CAP group, retinal inflammation and tissue injury were more pronounced than in the other groups, accompanied by higher clinical and histopathological scores and increased IL-17A levels in the colon and spleen. High-dose CAP was also associated with ileal architectural abnormalities, reduced colonic mucosal thickness, and decreased colonic ZO-1 and MUC2 expression. 16S rRNA gene sequencing revealed alterations in gut microbial diversity and community structure. CAP-associated differential metabolites were enriched in the tryptophan metabolism pathway, and fecal KYNA levels were significantly reduced. KEGG over-representation analysis identified significant enrichment of the IL-17 signaling pathway among CAP-upregulated genes, whereas GSEA was not significant after multiple-testing correction, upregulation of Conclusion: High-dose CAP exposure during EAU induction was associated with increased disease severity, accompanied by disrupted intestinal homeostasis, reduced fecal KYNA levels, and enhanced IL-17-related inflammation. KYNA co-treatment partially attenuated CAP-associated ocular and intestinal alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.